Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 7/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 9/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 9/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105828 | 0.91 | ACVRL1 (0.39) | ACVRL1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL7605044 | 0.89 | ACVRL1 (0.39) | ACVRL1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL26944060 | 0.83 | ACVRL1 (0.43) | ACVRL1PIK3CD | |
| SCHEMBL14642544 | 0.83 | ACVRL1 (0.41) | ACVRL1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL7605058 | 0.83 | ACVRL1 (0.44) | ACVRL1PIK3CD | |
| SCHEMBL7602181 | 0.80 | PIK3CD (0.42) | ACVRL1PIK3CD | |
| SCHEMBL14642530 | 0.80 | ACVRL1 (0.36) | ACVRL1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL14642529 | 0.80 | PIK3CD (0.37) | ACVRL1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL7602863 | 0.77 | ACVRL1 (0.43) | ACVRL1PIK3CD | |
| SCHEMBL14642736 | 0.76 | ACVRL1 (0.45) | ACVRL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-17 | — | — | US | disclosed |
| US-8119607-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-21 | — | — | US | disclosed |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ACVRL1 4215/4885CSNK2A2 4716/4885CSNK2A1 4695/4885 |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ACVRL1 4215/4885CSNK2A2 4716/4885CSNK2A1 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.